EN | TR
E-ISSN: 2980-261X
The Effect of Right Ventricular Systolic Functions and Pulmonary Arterial Pressure on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
PDF
Cite
Share
Request
Original Research
VOLUME: 1 ISSUE: 2
P: 43-47
August 2023

The Effect of Right Ventricular Systolic Functions and Pulmonary Arterial Pressure on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Bull Crdiov Acad 2023;1(2):43-47
DOI: 10.4274/kvbulten.galenos.2023.25733
Sıla Çelik 1
Ajar Koçak 2
Melis Çiçek 2
Ebru Ercan 2
1. Ufuk Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye
2. Ufuk Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye
No information available.
No information available
Received Date: 20.08.2023
Accepted Date: 28.08.2023
Publish Date: 18.09.2023
PDF
Cite
Share
Request

ABSTRACT

Objective:

In the literature, the tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio <0.55 mm/mmHg has been expressed as a predictive risk factor for pulmonary hypertension. In addition, the TAPSE/sPAP ratio ≤0.32 mm/mmHg has been reported as a predictive risk marker for all-cause mortality. In this study, we compared patients with type 2 diabetes mellitus (DM) with healthy volunteers in terms of cardiovascular outcomes with TAPSE/sPAP ratio.

Material and Methods:

In this study, diabetic patients were compared with healthy volunteers for the TAPSE/sPAP ratio determined by transthoracic echocardiography. Echocardiographic procedures were performed by 2 different cardiologists blinded to the clinical status of the patients. The independent association between type 2 DM and TAPSE/sPAP ratio was statistically evaluated using IBM Statistics 21.

Results:

In this study, 37 diabetic patients were compared with 38 healthy controls in terms of echocardiographic parameters (total 75 patients, mean age: 67.1±9.5). 69.3% of the patients were male. body mass index values of diabetic patients were slightly elevated (28.6±4.4 vs. 27.3±4.6; p=0.154). Statistically significant decrease in ejection fraction (%) values was detected in diabetic patients (p=0.037). When diastolic functions were evaluated, the rate of diastolic dysfunction on a trend basis was higher in diabetic patients compared to controls (p=0.055). TAPSE values also tended to decrease in diabetics compared to non-diabetics (p=0.104). In addition, the estimated mean systolic pulmonary artery pressure values were found to be increased in diabetics (p<0.001). TAPSE/SPAP ratio, which was reported to be predictive of adverse cardiovascular outcomes, was found to be decreased in diabetics compared to non-diabetics (p<0.001).

Conclusions:

In this study, the TAPSE/sPAP ratio, which can be easily applied in clinical practice, was found to be lower in diabetic patients compared to non-diabetic controls. Accordingly, decreased TAPSE/SPAP ratio values in diabetic patients compared to healthy individuals may be predictive of adverse cardiovascular outcomes.

Keywords:
TAPSE/sPAP ratio, cardiovascular outcomes, diabetics

References

1
Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: Department of Health and Human Services, CDC, 2011.
2
Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report. Estimates of Diabetes and Its Burden in the United States, 2022.
3
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-820. 
4
Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest 2005;128(5):3568-3571. 
5
Kjaergaard J, Petersen CL, Kjaer A, Schaadt BK, Oh JK, Hassager C. Evaluation of right ventricular volume and function by 2D and 3D echocardiography compared to MRI. Eur J Echocardiogr 2006;7(6):430-438.
6
Spiro JR, Steeds RP. Chapter 14 - Echocardiography in Respiratory Medicine, Editor(s): Stephen G. Spiro, Gerard A. Silvestri, Alvar Agustí, Clinical Respiratory Medicine (Fourth Edition), W.B. Saunders, 2012;193-201.
7
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18(12):1440-1463.
8
Wiedemann HP, Matthay RA. Acute right heart failure. Crit Care Clin 1985;1(3):631-661.
9
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618-3731.
10
Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009;33(2):318-324.
11
Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011;30(8):904-911.
12
Abernethy AD, Stackhouse K, Hart S, Devendra G, Bashore TM, Dweik R, et al. Impact of diabetes in patients with pulmonary hypertension. Pulm Circ 2015;5(1):117-123.
13
Colalillo A, Hoffmann-Vold AM, Pellicano C, Romaniello A, Gabrielli A, Hachulla E, et al. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Autoimmun Rev 2023;22(4):103290.
14
Bull TM, Clark B, McFann K, Moss M; National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2010;182(9):1123-1128.
15
Kopeć G, Waligóra M, Tyrka A, Jonas K, Pencina MJ, Zdrojewski T, et al. Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep 2017;7:41650.
16
Jonas K, Waligóra M, Magoń W, Zdrojewski T, Stokwiszewski J, Płazak W, et al. Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension. Arch Med Sci 2019;15(6):1397-1406.
17
Hill MF. Diabetic cardiomyopathy: Cardiac changes. Pathophysiological mechanisms. Biologic markers and the available therapeutic armamentarium. In: Cardiomyopathies - from basic research to clinical management. Veselka J (Ed) 2012:487-512.
18
Feuvray D. Cardiac metabolism in the diabetic patient. Heart Metab 2010;46:11–15.
19
Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, et al . Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010;12(9):951-957.
20
From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010;55(4):300-305.